Charcot Marie Tooth Disease Clinical Trial
— 6604Official title:
Development and Validation of a Disability Severity Index for Charcot Marie Tooth Disease
Verified date | March 2014 |
Source | University of Iowa |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Institutional Review Board |
Study type | Observational |
It is necessary for outcome measures to accurately reflect the state of health of a person in order for clinical trials to show benefit. The most commonly used outcome measure for Charcot Marie Tooth Disease (CMT) is the CMT Neuropathy Score, which uses cutoffs of points designated as mild (0-10 points), moderate (11-20) or severe (21-36). These terms are arbitrary. This study is looking to base mild, moderate, and severe on what both people affected with CMT and those who provide for people with CMT consider appropriate.
Status | Completed |
Enrollment | 291 |
Est. completion date | March 2014 |
Est. primary completion date | March 2014 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Both |
Age group | 8 Years and older |
Eligibility |
Inclusion Criteria: - patients with CMT ages 8-100, - health care professionals who take care of patients with CMT. - Eligible patients will be patients that have joined the INC RDCRN Contact Registry. These will be patients or guardians with known or probable inherited neuropathies. - Eligible health care professionals who participate in the care of patients with inherited neuropathies (physicians, genetic counselors, physical and occupational therapists etc.) attending the 4th International CMT Consortium to be held in Potomac Maryland June 29-July 1, 2011. Exclusion Criteria: - Does not read or speak English. |
Observational Model: Cohort, Time Perspective: Prospective
Country | Name | City | State |
---|---|---|---|
United States | University of Iowa | Iowa City | Iowa |
Lead Sponsor | Collaborator |
---|---|
University of Iowa | Muscular Dystrophy Association, National Institute of Neurological Disorders and Stroke (NINDS) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Compare Patient and Healthcare Provider impressions of what constitutes mild, moderate and severe impairment in CMT | 1 year | No | |
Secondary | Develop a Disability Severity Index including items with high patient-physician concordance | 1 year | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02561702 -
Mexiletine for Muscle Cramps in Charcot Marie Tooth Disease
|
Phase 2 | |
Completed |
NCT00541164 -
Effects of Coenzyme Q10 on Charcot-Marie-Tooth Disease
|
Phase 1/Phase 2 | |
Recruiting |
NCT01918826 -
Evaluation of the Analgesic Efficiency of the Transcutaneous Neurostimulation in the Charcot Syndrome Marie Tooth on the Pains of Lower Limbs
|
N/A | |
Completed |
NCT02194010 -
Disability Severity Scale (DSI) and Hereditary Motor and Sensory Neuropathy Overall Disability Scale (HMSN-R-ODS)
|
||
Recruiting |
NCT01203085 -
Development of Charcot Marie Tooth Disease (CMT) Pediatric Scale for Children With CMT
|
||
Recruiting |
NCT01193075 -
Natural History Evaluation of Charcot Marie Tooth Disease (CMT) Types CMT1B, CMT2A, CMT4A, CMT4C, and Others
|